Results 1 to 10 of about 2,710 (165)
Effects of Aliskiren Monotherapy on Chronic Kidney Disease: A Systematic Review and Meta‐Analysis of Blood Pressure and Urinary Protein Excretion Outcomes [PDF]
The Journal of Clinical HypertensionAliskiren has been proposed as an alternative for renin‐angiotensin system blockage in chronic kidney disease (CKD); however, its efficacy and safety remain uncertain.
N M Mahmudul Alam Bhuiya +3 more
doaj +3 more sources
Circulation, 2008 Aliskiren is the first orally active inhibitor of renin to be approved for clinical use as an antihypertensive agent. The development program has established that at the licensed doses of 150 mg and 300 mg, there are dose-related falls in blood pressure comparable to those seen with other major classes of antihypertensive drugs and that these falls are
Morris Brown
exaly +6 more sources
Prorenin in Hepatic Stellate Cell Extracellular Vesicles Induces Platelet-Dependent Thrombin Formation and Release of Profibrotic TGF-β. [PDF]
FASEB JPlatelets interact with extracellular vesicles shed by hepatic stellate cells to activate both cell types. Extracellular vesicles shed by activated hepatic stellate cells contain inactive prorenin. HSC‐EV interact with quiescent platelets to non‐proteolytically activate ligated prorenin.
Chen R +8 more
europepmc +2 more sources
Real-world safety of aliskiren in primary hypertension: A cross-database study. [PDF]
PLoS ONEHypertension is one of the main causes of cardiovascular diseases worldwide, affecting over one billion people. Although aliskiren offers a valuable option for inhibiting the renin-angiotensin system, its safety profile in the real world remains ...
Meirong Shan +9 more
doaj +2 more sources
Kidney & Blood Pressure Research, 2023 Introduction: Renin-angiotensin system inhibitors have been reported to exert protective effects against organ damage and failure; however, the impact of the direct renin inhibitor as monotherapy has not been assessed.
Yasufumi Seki +8 more
doaj +2 more sources
Treatment combining aliskiren with paricalcitol is effective against progressive renal tubulointerstitial fibrosis via dual blockade of intrarenal renin. [PDF]
PLoS ONE, 2017 The aim of this study was to assess any potential additive effects of a treatment combining aliskiren with paricalcitol on reducing renal fibrosis. C57BL/6J mice were treated individually with aliskiren and/or paricalcitol until 7 days after initiation ...
Sungjin Chung +7 more
doaj +1 more source
Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure [PDF]
New England Journal of Medicine, 2016 Among patients with chronic heart failure, angiotensin-converting-enzyme (ACE) inhibitors reduce mortality and hospitalization, but the role of a renin inhibitor in such patients is unknown. We compared the ACE inhibitor enalapril with the renin inhibitor aliskiren (to test superiority or at least noninferiority) and with the combination of the two ...
Mcmurray, John J. V +15 more
openaire +11 more sources
Diabetology & Metabolic Syndrome, 2022 Background Diabetic hepatopathy is a serious complication of poorly controlled diabetes mellitus. An efficient antidiabetic drug which keeps normal liver tissues is not available.
Amal M. Mahfoz, Aya Y. Gawish
doaj +1 more source
Cardiology Research and Practice, 2020 Background. Studies show that aliskiren exerts favourable effects not only on endothelial progenitor cells (EPCs) but also on endothelial function. However, the mechanism of the favourable effect of aliskiren on EPCs from patients with hypertension is ...
Shun Yao +4 more
doaj +1 more source
BMC Cardiovascular Disorders, 2020 Background Aliskiren is a newly developed drug. Its role in lowering BP has been recognized. However, the role of aliskiren in treating heart and renal diseases are still controversial. Objective To evaluate the existing evidence about clinical efficacy,
Qiyuan Zhao +4 more
doaj +1 more source